-
German Company FUSE-AI Launches Groundbreaking AI Algorithm for Radiology to the Market
B3C newswire
January 29, 2024
As of January 2024, the company is authorized to distributeits software as a medical product.
-
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
PharmaSources
January 24, 2024
Jan. 24, 2024 - InnoCare Pharma announced today that the first pediatric patient has been dosed in clinical trial with its second.
-
Vetter Becomes a Member of the German Association of Research-Based Pharmaceutical Companies (vfa)
B3C newswire
January 19, 2024
Globally operating CDMO committed to strengthening Germany as a research and production location
Association grants Vetter extraordinary membership.
-
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
PharmaSources
January 16, 2024
ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.
-
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
B3C newswire
January 15, 2024
January 08, 2024 ,Pluri Inc.announced it has launched a new business division offering cell therapymanufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO™.
-
BD to Highlight its Deep Commitment to Drug Delivery Innovation at Pharmapack
B3C newswire
January 15, 2024
A leading global medical technology company, will showcase numerous drug delivery innovations at Pharmapack 2024, which will take place on January 24-25, 2024 at Paris Expo, Porte de Versailles, in Paris.
-
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
PharmaSources
November 15, 2023
InnoCare Pharma,announced today that 10 studies from InnoCare's oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
-
NecstGen and ProteoNic Report Development of Improved Viral Vectors through the Application of Premium 2G UNic™ Technology
B3C newswire
November 06, 2023
NecstGen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors.
-
Avantor Inaugurates Expanded Singapore Hub
PharmaSources
July 12, 2023
On July 11, 2023,Avantor, Inc. inaugurated its expanded Singapore Hub which includes newly added cGMP manufacturing and a world class quality control laboratory.
-
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
PharmaSources
February 24, 2023
InnoCare Pharma and Keymed Biosciences that the first subject has been dosed in clinical trial of ICP-B05.